COMPARISON OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY SCAN PATTERNS AND CLINICAL REVIEW STRATEGIES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Retina. 2015 Jul;35(7):1315-22. doi: 10.1097/IAE.0000000000000478.

Abstract

Purpose: To compare various spectral domain optical coherence tomography scan patterns and review strategies to identify an optimal imaging workflow for neovascular age-related macular degeneration.

Methods: A retrospective consecutive case series was performed in eyes after anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration with concurrent spectral domain optical coherence tomography imaging (Zeiss Cirrus), including horizontal/vertical five-line rasters, and macular cube analysis. For each scan pattern, a single report was independently reviewed in a masked fashion within the clinical image review software, whereas the cube was reviewed line-by-line in the reader software for the presence of fluid.

Results: One hundred and fifty-six reports and 39 cube scans of 39 patients were included. Among all spectral domain optical coherence tomography scans, 64% (25/39) had definitive fluid and 95% (37/39) had possible fluid. Sensitivities for definite fluid detection for horizontal, combined horizontal/vertical, and horizontal/vertical/map reviews were 68%, 76%, and 88%, respectively. When assessing for possible fluid, sensitivities for the detection for horizontal, combined horizontal/vertical, and horizontal/vertical/map reviews were 76%, 92%, and 97%, respectively. Line-by-line review of the cube scan had a sensitivity for definite and possible fluid detection of 96% and 86%, respectively.

Conclusion: Optimizing both clinical accuracy and workflow are important factors in managing neovascular age-related macular degeneration. A zero-tolerance strategy with vertical/horizontal raster scans and thickness maps was comparable with line-by-line review of the cube to detect possible fluid.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Humans
  • Retrospective Studies
  • Sensitivity and Specificity
  • Subretinal Fluid*
  • Tomography, Optical Coherence*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Wet Macular Degeneration / diagnosis*
  • Wet Macular Degeneration / drug therapy

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A